Disc Medicine (NASDAQ:IRON - Get Free Report)'s stock had its "overweight" rating reiterated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $170.00 price target on the stock. Cantor Fitzgerald's price objective suggests a potential upside of 118.00% from the stock's current price.
IRON has been the subject of several other reports. BMO Capital Markets raised their target price on shares of Disc Medicine from $100.00 to $120.00 and gave the company an "outperform" rating in a report on Monday, October 19th. Truist Financial boosted their target price on shares of Disc Medicine from $83.00 to $115.00 and gave the company a "buy" rating in a research note on Monday, October 19th. Morgan Stanley upped their target price on shares of Disc Medicine from $92.00 to $104.00 and gave the company an "overweight" rating in a report on Wednesday. Wedbush raised their price target on shares of Disc Medicine from $100.00 to $110.00 and gave the stock an "outperform" rating in a research note on Monday, October 19th. Finally, HC Wainwright lifted their price target on shares of Disc Medicine from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Friday, November 6th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $125.27.
Get Our Latest Stock Analysis on Disc Medicine
Disc Medicine Stock Performance
NASDAQ IRON opened at $77.98 on Thursday. The business's 50 day moving average is $71.57 and its two-hundred day moving average is $71.05. Disc Medicine has a 12-month low of $40.00 and a 12-month high of $99.50. The stock has a market capitalization of $3.55 billion, a price-to-earnings ratio of -12.30 and a beta of 0.96. The company has a current ratio of 20.30, a quick ratio of 20.30 and a debt-to-equity ratio of 0.10.
Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($1.53) EPS for the quarter, beating analysts' consensus estimates of ($1.63) by $0.10. Research analysts expect that Disc Medicine will post -6.20 EPS for the current year.
Insider Activity
In related news, COO Jonathan Yu sold 8,796 shares of the company's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the sale, the chief operating officer directly owned 54,324 shares of the company's stock, valued at approximately $4,515,410.88. This represents a 13.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kevin Bitterman sold 49,164 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $80.17, for a total value of $3,941,477.88. Following the completion of the sale, the director owned 13,499 shares of the company's stock, valued at approximately $1,082,214.83. This represents a 78.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 150,277 shares of company stock valued at $11,877,059. Company insiders own 3.76% of the company's stock.
Institutional Investors Weigh In On Disc Medicine
Several hedge funds have recently modified their holdings of IRON. BlackRock Inc. purchased a new position in Disc Medicine in the 2nd quarter worth approximately $180,502,000. Wellington Management Group LLP raised its stake in shares of Disc Medicine by 0.3% during the second quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company's stock valued at $127,362,000 after purchasing an additional 5,975 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Disc Medicine by 191.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company's stock valued at $73,280,000 after purchasing an additional 735,300 shares during the period. Opaleye Management Inc. lifted its position in shares of Disc Medicine by 103.1% during the second quarter. Opaleye Management Inc. now owns 855,000 shares of the company's stock worth $62,535,000 after purchasing an additional 434,000 shares in the last quarter. Finally, Aberdeen Group plc lifted its position in shares of Disc Medicine by 36.4% during the third quarter. Aberdeen Group plc now owns 597,841 shares of the company's stock worth $39,135,000 after purchasing an additional 159,667 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company's development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.